Plain-English translation of NCT06385652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new diagnostic imaging scan called PET to help detect multiple myeloma, a type of blood cancer that often goes undetected until it's advanced. The scan works by targeting a specific marker called CD38 that appears on cancer cells. Researchers want to see if this new scan can find myeloma earlier and more accurately than the standard imaging method currently used.
Multiple myeloma is increasingly common in aging populations but is often caught too late because current detection methods rely on invasive bone marrow biopsies that can miss cancer if the sample is taken from the wrong spot. This new treatment could provide a safer, non-invasive way to spot the disease early and help doctors create better personalized treatment plans.
You likely qualify if…
You likely don't qualify if…
You will receive two imaging scans on separate occasions. For each scan, a small radioactive tracer will be injected into your arm, and then you'll lie still on a scanning machine for about an hour while pictures are taken of your body from head to mid-thigh. One scan uses the new medication being tested, and the other uses the standard imaging method. The scans are painless and non-invasive, though you'll need to fast for 6 hours before one of them.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China